



Abbott India Ltd
Godrej BKC, Plot C-68, G. Block,
15-16th Floor, BKC,
Near MCA Club, Bandra (E),
Mumbai - 400 051. India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai -400 071. India

Tel : (91-22) 3816 2000
Fax : (91-22) 3816 2400
E-mail: webmaster@abbott.co.in
Site : www.abbott.co.in
CIN : L24239MH1944PLCO07330

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

November 28, 2019

Scrip Code: 500488

Dear Sirs,

Sub: Intimation under Regulation 23 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended September 30, 2019.

The above disclosure is also available on the website of the Company i.e. www.abbott.co.in

This is for your information and record.

Kindly acknowledge the receipt of the same.

Thank you.

Yours faithfully,
Abbott India Limited


Krupa Anandpara
Company Secretary
Membership No.: ACS 16536



Encl: a/a

#

RELATED PARTY DISCLOSURE**A. Parties where control exists:**

Ultimate Holding Company : Abbott Laboratories, USA

Holding Company : Abbott Capital India Limited, UK

B. Other related parties with whom transactions have taken place during the year:**I) Fellow subsidiaries :**

British Colloids Ltd., U.K.
Abbott Healthcare Products Ltd., U.K
Abbott Healthcare Private Ltd, India
Abbott International LLC, USA
Abbott Products Operations AG, Switzerland
Abbott Laboratories (Singapore) Pte Ltd., Singapore
Abbott Manufacturing Pte Ltd., Singapore
Abbott GmbH & Co. K.G., Germany
Alere Medical Private Limited, India
Abbott Laboratories S.A., Switzerland
Abbott Laboratories S.A., Dubai
Abbott Laboratories S.C., Srilanka

II) Key Management personnel:

Mr. Ambati Venu, Managing Director
Mr. Rajiv Sonalker, Whole-Time Director
Mr. Munir Shaikh, Chairman
Mr. Krishna Mohan Sahnii, Independent Director
Ms. Anisha Motwani, Independent Director

C. Transactions during the year :

(Rupees in Lakhs)

(1) Transactions with the Holding Company during the year

	Period from April 1, 2019 to September 30, 2019
Abbott Capital India Ltd., UK	
Remittance of Dividend	6,967.41

(II) Transactions with Fellow Subsidiaries during the year**(i) Remittance of dividend :**

	Period from April 1, 2019 to September 30, 2019
British Colloids Ltd., U.K.	
Remittance of Dividend	955.50
Abbott Healthcare Products Ltd., U.K	
Remittance of Dividend	2,434.22

(ii) Sales to fellow subsidiaries :

	Period from April 1, 2019 to September 30, 2019
Abbott Healthcare Private Ltd, India	
Sales of Stock-in-trade	2,932.14
Sales of Raw Materials	2,940.57
Abbott Products Operations AG, Switzerland	
Sales of Stock-in-trade	35.75

(iii) Purchases from fellow subsidiaries:

	Period from April 1, 2019 to September 30, 2019
Abbott Healthcare Private Ltd, India	
Purchase of Raw Materials	491.58
Purchase of Stock-in-trade	8,336.37



Abbott Products Operations AG, Switzerland	
Purchase of Raw Materials	16,656.95
Purchase of Stock-in-trade	4,029.21

(iv) Other expenses to fellow subsidiary :

	Period from April 1, 2019 to September 30, 2019
Abbott Healthcare Private Ltd, India	
Promotional Expenses	12.61
Conversion charges	805.31
Alere Medical Pvt. Ltd., India	
Promotional Expenses	5.63

(vii) Reimbursements to and from fellow subsidiaries:

	Reimbursement to	Reimbursement from
	Period from April 1, 2019 to September 30, 2019	Period from April 1, 2019 to September 30, 2019
Abbott Healthcare Private Ltd, India		
Shared and support Services	507.00	-
Rent Expenses	1,680.30	-
Market Research and other Expenses		0.57
Abbott International LLC, USA		
Employee Benefit Expenses, Travel and other Expenses	27.68	-
Abbott Laboratories (Singapore) Pte Ltd., Singapore		
Employee Benefit Expenses, Travel and other Expenses	26.80	7.53
Abbott Products Operations AG., Switzerland		
Employee Benefit Expenses, Travel and other Expenses	-	131.83
Abbott Laboratories S.A., Switzerland		
Employee Benefit Expenses, Travel and other Expenses		9.51
Abbott Laboratories S.C., Srilanka		
Employee Benefit Expenses, Travel and other Expenses		13.86

(viii) Income from fellow subsidiaries:

	Period from April 1, 2019 to September 30, 2019
Abbott Healthcare Private Ltd, India	
Shared and support services	813.00
Rent Income	57.26
Abbott Products Operations AG., Switzerland	
Shared and support services	147.86
Abbott Laboratories (Singapore) Pte, Singapore	
Shared and support services	54.00
Abbott Laboratories S.A., Dubai	
Shared and support services	54.00

(ix) Key management personnel remuneration :

	Period from April 1, 2019 to September 30, 2019
Executive Directors and Key Managerial Personnel	251.00

(x) Non-Executive, Other Director's sitting fees:

	Period from April 1, 2019 to September 30, 2019
Sitting Fees to Independent Directors	28.00

D. Outstanding	As at September 30, 2019
Trade payable to fellow subsidiaries	
Abbott Products Operations AG., Switzerland	11,513.41



Abbott Healthcare Private Ltd, India	2,536.86
	14,050.27
Other payable to fellow subsidiaries	
Abbott International LLC, USA	17.15
Abbott Laboratories S.A., Switzerland	23.48
	40.62
Trade receivables from fellow subsidiaries	
Abbott Healthcare Private Ltd, India	2,736.32
	2,736.32
Other receivables from fellow subsidiaries	
Abbott Healthcare Private Ltd, India	0.13
Abbott Products Operations AG., Switzerland	130.33
Abbott Laboratories S.C., Srilanka	14.12
Abbott Laboratories S.A., Dubai	9.06
Abbott Laboratories (Singapore) Pte, Singapore	16.47
	170.11
Loan and deposit to fellow subsidiaries	
Abbott Healthcare Private Ltd, India	1,467.68

Terms and conditions of transactions with related parties :

All transactions with related parties are made in the ordinary course of business and the same is at arm's length. Outstanding balances at the year-end are unsecured and settlement occurs in cash. The Company has not recorded any impairment of receivables. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which related party operates.

